Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vascular Injury, Amyloid, and Tau in Post-Stroke Cognitive Dysfunction
NCT04588649Phase 2Completed
- Sponsor
- Chang Gung Memorial Hospital
- Start
- Jan 2016
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of 18F-THK5351, Florbetapir in Post-stroke dementia (PSD), vascular mild cognitive impairment (VaMCI), sponsored by Chang Gung Memorial Hospital. Started Jan 2016; status: completed.
02
Drugs
18F-THK5351Florbetapir
03
Conditions
Post-stroke dementia (PSD)vascular mild cognitive impairment (VaMCI)
Beyond the preview
Go deeper on NCT04588649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04588649.